Sotorasib and adagrasib, both KRAS G12C inhibitors, have demonstrated significant success in clinical trials improving progression-free-survival in non-small cell lung cancer (60,61), while belvarafenib has recently shown promise in targeting NRAS mutations in a phase Ib clinical trial including patients with BRAFV600E- and NRAS-mutant melanoma (62). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.